https://www.selleckchem.com/pr....oducts/Clopidogrel-b
Most children with intermediate-risk rhabdomyosarcoma (RMS) have gross disease (group III) at the initiation of chemotherapy. Delayed primary excision (DPE) after induction chemotherapy allows for a reduction in adjuvant radiation dose, but with the risk of potential surgical morbidity. The objectives of this study were to compare outcomes in children with group III RMS who did and did not undergo DPE and to assess surgical morbidity. The study included 369 patients who had clinical group III RMS at sites amenable to DPE f
Like
Comment
Share
